Article Text

other Versions

The natural history of Stevens-Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy
  1. Victoria de Rojas (vderojas{at},
  2. John K.G. Dart (j.dart{at},
  3. Valerie Saw (v.saw{at}
  1. Fundación Instituto Galego de Oftalmoloxía, Spain
  2. Cornea and External Disease Service, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, United Kingdom
  3. Cornea and External Disease Service, Moorfields Eye Hospital, 162 City Rd, London EC1V 2PD, United Kingdom


    Purpose: To characterize patterns of chronic ocular disease in patients with Stevens-Johnson syndrome (SJS) and its variant Toxic Epidermal Necrolysis (TEN), and to describe their response to treatment.

    Design: Retrospective case series.

    Participants: Thirty patients (sixty eyes) with ocular manifestations of SJS or TEN.

    Methods: Hospital records review.

    Main Outcome Measures: The principal outcome measure was to identify and classify the patterns of chronic ocular disease in SJS and TEN. The secondary outcome measure was the response to treatment.

    Results: Patterns of chronic ocular disease observed after the acute episode included: Mild/Moderate SJS, Severe SJS, ocular surface failure (SJS-OSF), recurrent episodic inflammation (SJS-RI), scleritis (SJS- S) and progressive conjunctival cicatrisation resembling mucous membrane pemphigoid (SJS-MMP). The median follow up was 5 years (range 0 to 29). 19 patients (29 eyes [48%]) developed SJS-OSF, SJS-RI, SJS-S or SJS-MMP during follow up. SJS-OSF was present in 12 patients (18 eyes [30%]). In 5 patients (8 eyes) this developed one year after the acute illness, without any further inflammatory episodes, it was associated with SJS-RI in 1 patient (2 eyes), with SJS-RI and SJS-S in 1patient (1 eye), SJS-S in 1 patient (1 eye) and with SJS-MMP in 4 patients (6 eyes). Episodes of SJS-RI occurred in 4 patients (7 eyes [12%]). The median time from acute disease to the first episode of SJS-RI was 8.5 years (range 5-63). SJS-S developed in 2 patients (4 eyes [7%]), of which 2 eyes subsequently developed SJS-OSF. SJS-MMP developed in 5 patients (10 eyes [16.6%]). The median duration from the acute stage to the diagnosis of SJS-MMP was 2 years (range 1-14). Immunosuppressive therapy successfully controlled inflammation in 10/10 patients with SJS-MMP, SJS-RI or SJS-S.

    Conclusion: Ocular disease in SJS/TEN is not limited solely to the sequelae of the acute phase illness. Patients and physicians need to know that ocular disease progression, due to surface failure and/or acute inflammatory conditions, may occur at variable periods following the acute disease episode. Recognition of this, and prompt access to specialist services, may optimise management of these uncommon patterns of disease in SJS.

    • Mucous membrane pemphigoid
    • Ocular surface failure
    • Recurrent inflammation
    • Scleritis
    • Stevens-Johnson syndrome

    Statistics from

    Review history and Supplementary material

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • BJO at a glance
      Creig Hoyt